医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AVITA Medical Added to the S&P/ASX 300 Index

2019年09月06日 PM02:40
このエントリーをはてなブックマークに追加


 

VALENCIA, Calif., & MELBOURNE, Australia

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019.

“We are pleased to be included in the S&P/ASX 300 index, which is a reflection of the increased market capitalization and trading liquidity the company has achieved this year while advancing the development and commercialization of our innovative regenerative medicine technology platform,” said Dr. Michael Perry, AVITA Medical’s Chief Executive Officer. “We believe AVITA Medical remains an attractive security as we work to expand the use of the RECELL® System to advance patient care and address unmet medical needs across numerous dermatological indications.”

The S&P/ASX family of indices measures the performance of ASX-listed companies across various sizes, industries, themes and strategies. Each index is designed to represent a certain segment of the Australian equities market. The S&P/ASX 300 Index, which is rebalanced semi-annually, measures the performance of the largest 300 companies based on market capitalisation on the ASX.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION(RES™), an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 7,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets outside of Europe, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia, CFDA-cleared in China, and received CE-mark approval in Europe.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190905006079/en/

CONTACT

AUS Media

Monsoon Communications

Sarah Kemter

Phone +61 (0)3 9620 3333

Mobile +61 (0)407 162 530

sarahk@monsoon.com.au

Investors:

Westwicke Partners

Caroline Corner

Phone +1-415-202-5678

caroline.corner@westwicke.com

AVITA Medical Ltd

Timothy Rooney

Chief Administrative Officers

And Interim Chief financial Officer

Phone +1 661 367 9161

trooney@avitamedical.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories announces launch of Doxercalciferol Injection in the U.S. Market
  • 海外の専門家によれば、リヤドは持続可能な都市への道を進んでいる
  • Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
  • Zymeworks在ESMO亚洲大会上宣布推进与百济神州的临床合作并公布ZW25用于治疗HER2呈阳性癌症患者的1期临床研究更新数据
  •  Phenomics Health Inc. 收购专利药物代谢组技术